BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BioCentury | Jan 11, 2016
Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
BC Week In Review | Jul 14, 2014
Clinical News

Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

Germany’s Federal Joint Commission (G-BA) issued a final benefit assessment saying HIV drug Eviplera emtricitabine/tenofovir/rilpivirine from Gilead has “no additional benefit” vs. individualized antiretroviral therapy in previously treated HIV patients - an indication the European Commission...
BioCentury | Jul 14, 2014
Finance

2Q Stock Wrap-Up: Large and in charge

In contrast to the first quarter in which all market cap segments gained ground, only the large caps finished 2Q14 in the black. Gainers outnumbered decliners 20-12 in the over $5 billion segment, which was...
BC Week In Review | Apr 7, 2014
Clinical News

Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that HIV drug Eviplera emtricitabine/tenofovir/rilpivirine from Gilead has "no additional benefit" vs. individualized antiretroviral therapy in previously treated HIV patients...
BC Extra | Apr 2, 2014
Company News

IQWiG rebuffs Gilead's HIV drug Eviplera

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that HIV drug Eviplera emtricitabine/tenofovir/rilpivirine from Gilead Sciences Inc. (NASDAQ:GILD) has "no additional benefit" vs. individualized antiretroviral therapy in previously...
BioCentury | Feb 10, 2014
Finance

Confident roll of the dice(r)

Underwriters for Dicerna Pharmaceuticals Inc. 's IPO took the rare step of waiving a lockup period for the RNAi play - a move that could give some existing shareholders a free hand to immediately realize some...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BC Week In Review | Dec 23, 2013
Clinical News

Complera regulatory update

FDA approved an sNDA from Gilead for Complera emtricitabine/tenofovir/rilpivirine for use as an alternative regimen for the treatment of HIV-1 infection in certain virologically suppressed (HIV-1 RNA <50 copies/mL) adult patients who are on a...
Items per page:
1 - 10 of 60